Foundation Medicine, Inc.

Foundation Medicine, Inc. develops genomic profiling tests that guide treatment strategies for cancer patients. The company provides FoundationOne CDx, a tissue-based companion diagnostic test for solid tumors; FoundationOne Liquid CDx, a blood-based companion diagnostic test for solid tumors; and a laboratory developed test for hematologic malignancies, sarcomas, or solid tumors. It also offers biopharma partner services. Foundation Medicine, Inc. was formerly known as Foundation Genomics, Inc. and changed its name to Foundation Medicine, Inc. in February 2010. The company was incorporated in 2009 and is based in Cambridge, Massachusetts with additional locations in Morrisville, North Carolina; Penzberg, Germany; and San Diego, California. As of January 31, 2022, Foundation Medicine, Inc. operates as a subsidiary of Roche Holdings, Inc.